SCP
VIR icon

Sender Company & Partners’s Vir Biotechnology VIR Stock Holding History

Sender Company & Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,175
Closed -$247K – 433
2025
Q3 		$247K Buy
+43,175
New +$221K 0.03% 373

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Sender Company & Partners's VIR Position: Q4 2025 in Review

Sender Company & Partners sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 43,175 shares — an estimated $247K sold.

Sender Company & Partners first reported a position in VIR in Q3 2025 and held it in 1 quarter. The position peaked at $247K in Q3 2025. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • Sender Company & Partners reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 43,175 Vir Biotechnology shares in Q4 2025, an estimated $247K.
  • Sender Company & Partners first reported a position in Vir Biotechnology in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Vir Biotechnology position peaked at $247K in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.